A 68-year-old man with stage IVA lung adenocarcinoma harboring an uncommon EGFR L861Q mutation and a programmed death-ligand 1 (PD-L1) tumor proportion score of <1% received first-line osimertinib (80 mg once daily) for nine months, achieving a partial response before disease progression. Here, EGFR is linked to neoplasm.